Kemal Balic

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani et al. · Leukemia · 2018 · 247 citations · Full text

Medicine, Oncology, Pharmacology +16

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

Mark D. Pegram, Erika Hamilton, Antoinette R. Tan et al. · Molecular Cancer Therapeutics · 2021 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease

Sergei Pechenov, Jefferson D. Revell, Sarah Will et al. · Scientific Reports · 2021 · 74 citations · Full text

Pharmacy, Endocrinology, Pharmacology +17

Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody–Drug Conjugate

Yue Huang, Christopher J. Del Nagro, Kemal Balic et al. · Analytical Chemistry · 2020 · 32 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Results from an international phase 2 study of the anti‐CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B‐lineage acute lymphoblastic leukemia

Nirali N. Shah, Deepa Bhojwani, Keith J. August et al. · Pediatric Blood & Cancer · 2020 · 22 citations · Full text

Medicine, Oncology, Pharmacology +17